Neuren Pharmaceuticals Updates on Buy-Back Program

The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of June 4, 2025, the company has bought back a total of 3,807,431 ordinary fully paid securities, including 19,002 securities purchased on the previous day. This buy-back initiative is part of the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its innovative approach to treating conditions such as Rett syndrome and Fragile X syndrome, positioning itself as a key player in the niche market of neurological therapeutics.

Average Trading Volume: 752,997

Technical Sentiment Signal: Buy

Current Market Cap: A$1.73B

For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.